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ABSTRACT
Objective. We explored to what extent experienced neuropsychologists can predict
distorted symptom presentation of clinically referred hospital outpatients. Method.
Using clinical files and interview results, 31 neuropsychologists made predictions as
to how 203 patients would perform on two response validity tests. Their predictions
were matched against actual passing or failing two such tests, of which one measured
overreporting of symptoms and the other underperformance on cognitive tests. Results.
Clinical predictions and test outcomes agreed in 76% of the cases, with Cohen’s kappa
being .26, 95% confidence interval, CI [.08, .44]. Of the 152 patients for whom neurop-
sychologists had predicted nondistorted symptom presentations, 14 patients (9.2%)
failed both response validity tests. Of the 51 patients for whom neuropsychologists had
predicted problematic response validity, 35 patients (68.6%) passed both tests.
Conclusions. Clinical prediction of distorted symptom presentation is far from perfect.
Our findings show that response validity tests have incremental value in that they may
correct initial clinical judgment.
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Several studies have found that neuropsychologists
are not very good at detecting distorted symptom
presentations in their patients. For example,
Heaton, Smith, Lehman, and Vogt (1978) provided
10 neuropsychologists with cognitive test profiles
of instructed feigners and head-injured patients.
The neuropsychologists had to determine whether
profiles reflected genuine impairment or feigning.
Their accuracy was far from perfect and ranged
from chance level to 20% above chance. Similar
results were reported by Faust, Hart, and
Guilmette (1988) and Faust, Hart, Guilmette, and
Arkes (1988). These authors found that the major-
ity of neuropsychologists seemed to believe that
the cognitive test profiles of adolescents and chil-
dren instructed to feign reflected cortical dysfunc-
tion. Without forewarning on the base rate of
malingering, none of the experts indicated feigning
as a plausible explanation of the test results.
These older studies are, however, not without
limitations (see for a critical review, Garb &
Schramke, 1996). They were carried out in an era
when distorted symptom presentation was under-
researched, and clinicians had only few tools to
screen for it (e.g., Merten et al., 2013). Since the
early nineties, there has been a steady increase in
empirical and meta-analytic studies evaluating the
diagnostic accuracy of tools designed to identify dis-
torted symptom presentation (e.g., Sweet & Guidotti
Breting, 2013). In keeping with the terminology of
other authors (Larrabee, 2012; Van Dyke, Millis,
Axelrod, & Hanks, 2013), we use response validity
tests as an overarching term for these tools. Broadly
speaking, there are two types of response validity
tests: (a) self-report symptom validity tests (SVTs)
that intend to measure overreporting of symptoms,
and (b) performance validity tests (PVTs) that assay
underperformance on cognitive tests (Greve,
Bianchini, & Brewer, 2013).
Major professional organizations in neuropsy-
chology have issued policy statements that stress
the routine use of SVTs and PVTs (National
Academy of Neuropsychology, Bush et al., 2005;
American Academy of Neuropsychology,
CONTACT Brechje Dandachi-FitzGerald b.fitzgerald@maastrichtuniversity.nl School for Mental Health and Neuroscience, Maastricht
University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
Supplemental data for this article can be accessed here.
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 2016
http://dx.doi.org/10.1080/13803395.2016.1223278
© 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Heilbronner, Sweet, Morgan, Larrabee, & Millis,
2009). These developments reflect neuropsycholo-
gists’ increased sensitivity to the diagnostic option
of distorted symptom presentation and how it can be
evaluated with specific tests. Indirect support for this
increased awareness comes from a study by
Trueblood and Binder (1997), who provided their
experts with protocols of clinical cases of feigning
rather than protocols of experimental (i.e.,
instructed) simulators. These protocols included
SVT and PVT results. The authors found that the
percentage of false negatives (i.e., missed feigned test
protocols) across experts varied between 0 and 25%
(Trueblood & Binder, 1997). Although neuropsy-
chologists in this study were better able to detect
symptom distortion than were experts in older stu-
dies (e.g., Faust, Hart, Guilmette, & Arkes, 1988),
Trueblood and Binder (1997) relied on strongly dis-
torted test profiles (e.g., below chance performance
on a PVT), when in practice less extreme cases are
more common and are usually the cases of greatest
concern. Accordingly the potential of false negatives
might be higher than 25%. Still, even if one would
accept 25% as an upper bound estimate of false
negatives, there is room for considerable
improvement.
Can neuropsychologists accurately predict dis-
torted symptom reporting prior to the administra-
tion of any SVTs and/or PVTs? This is an important
question whenever response validity tests are not
incorporated in test batteries per default. In a recent
survey among European neuropsychologists
(Dandachi-FitzGerald, Merten, & Ponds, 2013),
only 12% of the respondents indicated that they
included response validity tests in every or nearly
every clinical neuropsychological assessment. Thus,
many European neuropsychologists will be regularly
confronted with the question of whether or not they
should add response validity tests to their test battery.
Yet, can neuropsychologists reliably predict on the
basis of their clinical impression whether SVTs/PVTs
have incremental value? Our study addressed this
issue. We anticipated that neuropsychologists
would not be particularly accurate in predicting the
outcome of these tests, and more specifically that
they would underestimate poor response validity.
After all, the limited accuracy of clinical judgment
was the primary reason to develop psychometric
approaches to detect distorted symptom presenta-
tion (Wedding & Faust, 1989). Thus, we examined
howwell experienced neuropsychologists can predict
the outcome of response validity testing in a
heterogeneous group of general hospital outpatients
referred for neuropsychological evaluation.
Method
Participants
This study is part of a larger research project on
SVT/PVT failure in clinically referred hospital out-
patients and how such failure relates to perfor-
mance on standard clinical instruments and
external incentives (Dandachi-FitzGerald, Van
Twillert, Van De Sande, Van Os, & Ponds, 2015).
In total, 31 neuropsychologists in five hospitals in
the southern part of the Netherlands participated
in the study. At the end of the Dandachi-
FitzGerald et al. (2015) study, clinicians received
an exit questionnaire (see below) that asked for
additional background information. All in all, 29
(94%) experts returned the questionnaire. Table 1
gives background information about this group.
On average, clinicians had 10 years of experience,
and more than two thirds of them were certified
clinical psychologist/neuropsychologist or certified
psychologist (i.e., psychologists with two-year
postgraduate clinical training).
The initial sample consisted of 469 patients
(52.7% women), with a mean age of 47.7 years
(SD = 14.0, range = 17–78), who were referred for
(neuro)psychological evaluation on the basis of med-
ical considerations. Patients with severe cognitive
impairment (e.g., moderate–severe Alzheimer’s dis-
ease, posttraumatic amnesia) were excluded. The
main five diagnostic categories upon referral were:
neurological conditions (24.1%), morbid obesity
(20.5%), medically unexplained symptoms (MUS;
18.1%), psychiatric disorders (15.8%), and cognitive
complaints not further specified (15.1%). A total of
203 patients (43.1%) received social security benefits
(full or partial), and 77 patients (16.4%) were
involved in legal proceedings at the time of the
assessment. Of the initial sample, 292 patients
(62.3%) were referred for neuropsychological evalua-
tion between July 2012 and May 2013, and it is this
subgroup that is considered below. All diagnostic
assessments were conducted for clinical purposes.
Detailed information about the patient sample is
given in Dandachi-FitzGerald et al. (2015).
Only protocols that contained data on clinicians’
predictions and the outcomes of two response valid-
ity tests—the Amsterdam Short Term Memory Test
(ASTM) and the Structured Inventory of Malingered
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Symptomatology (SIMS; see below)—were included
in the final analyses. There were eight cases with
missing data on the ASTM, eight cases with missing
data on the SIMS, and five cases with missing pre-
diction data. These 21 assessments were excluded,
leaving 271 cases for the final analysis.
In patient samples seen for clinical assessment, the
base rate of poor symptom validity is estimated to be
around 10% (Dandachi-FitzGerald et al., 2013;
Mittenberg, Patton, Canyock, & Condit, 2002). With
such a relatively low frequency, aggregating results
across multiple response validity indicators reduces
the probability of false positives (Larrabee, 2008).1
Given a base rate of 10%, the posttest probability of
poor response validity when both SIMS and ASTM
are failed is .93. The posttest probability of valid
responding when both SIMS and ASTM are passed
is .99. With this in mind, two groups were selected
from the pool of 271 cases: a group of patients who
passed both response validity tests (n = 173), and a
group of patients who failed both response validity
tests (n = 30).2 The characteristics of these two groups
are given in Table 2. As can be seen, the majority of
patients in both groups had been diagnosed upon
referral with a neurological condition,medically unex-
plained symptoms, or a psychiatric disorder.
The research protocol was reviewed and
approved by the Medical Ethical Committee of
Maastricht University Medical Centre.
Measures
Symptom validity test (SVT): Structured
Inventory of Malingered Symptomatology (SIMS)
Test protocols included a Dutch research version
of the SIMS (Merckelbach & Smith, 2003), which is
a self-report scale that consists of 75 true–false
Table 1. Background of neuropsychologists
Neuropsychologists Mean (range)
Age (years) 36.0 (27–62)
Years of work experience 10.4 (1.5–35)
Number of annual neuropsychological assessments 69.1 (5–230)
Increased sensitivity to symptom distortion due to
taking part in this study (0–10)
5.9 (1–9)
% sample
Sex (female) 79.3
Professional title
Professional title
Certified clinical psychologist/neuropsychologist
20.6
Clinical psychologist/neuropsychologist trainee 13.7
Certified psychologist (two-year postgraduate
training)
34.5
Psychologist trainee 24.1
Psychologist (only university degree) 6.9
Conducting forensic evaluations (mean number of
forensic evaluations in the past year; range)
41.4 (1.4; 0–4)
Administration of response validity tests prior to
start study forensic evaluations in the past year;
range)
Standard 24.1
Only certain situations 72.4
Never 6.9
Indications for administration of response validity
testsa
Indications for administration of response
validity testsa:
Symptom reports during interview
95.5
Presentation of the patient during the interview 100
Diagnosis upon referral*b 31.8
On request of referral party 22.7
When incentives are present (e.g.e.g., legal
procedures, disability claims)
90.9
Other**c 18.2
Note. N = 29.
aThere were seven missing responses for this question; percentages
are based on 22 responses. bType of diagnosis upon referral that
led to inclusion of symptom validity tests (SVTs): conversion, func-
tional symptoms, whiplash-associated disorders, chronic fatigue
syndrome, commotion cerebri, and personality disorder. cOther
indications: inconsistency in scores noticed during testing; impres-
sion of the technician during testing; behavioral presentation dur-
ing testing; stagnation of treatment.
Table 2. Characteristics of patients who passed or failed
both response validity tests
Patients who
failed both tests
Patients who
passed both tests
(n = 30) (n = 173)
Patients Mean (range) Mean (range)
Age (years) 54.6 (32–71) 48.6 (17–77)
Educationa 3.57 (1–8) 4.56 (1–8)
SIMS total score 26.7 (19.3–41) 8.85 (0–19)
ASTM total score 74.8 (60–81) 86.5 (82–90)
% sample % sample
Sex (female) 43.3 43.9
Main diagnostic categories
Neurological conditions 30.0 38.7
Medically unexplained
symptoms
20.0 17.0
Psychiatric disorders 23.3 11.0
Cognitive complaints not
further specified
16.7 25.4
Medical conditions with
cognitive complaints
3.3 4.0
Other 6.7 2.9
Missing 0 1.2
Note. N = 203. SIMS = Structured Inventory of Malingered
Symptomatology; ASTM = Amsterdam Short-Term Memory Test.
aEducation was quantified with an 8-point scale that ranges from
primary school (1; fewer than six years of education) to university
degree (8; 16 years of education or more) (De Bie, 1987).
1This is only true when indicators are relatively independent of one another. In the current study, the shared
variance (R2) between SIMS and ASTM was 16% (for the total sample; N = 271).
2Information on neuropsychologists’ prediction versus test performance for the subsample of patients who failed
one of either test is given in the supplemental file.
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items pertaining to rare and/or improbable symp-
toms. Endorsed items are summed to obtain a total
SIMS score, with higher scores indicating stronger
tendencies to overreport. A recent meta-analysis
combined 17 samples of nonoverreporting patients
(N = 742) and found for this group a weighted
total SIMS score of 16.1 with a 95% confidence
interval (CI) from 13.4 to 18.9 (Van Impelen,
Merckelbach, Jelicic, & Merten, 2014). Following
the recommendations of this meta-analysis, we
employed a cutoff of 19. In the initial sample
(N = 469), the rates of overreporting on the SIMS
(i.e., >19) ranged between 12% and 19% for the
main diagnostic subgroups, with a significantly
lower failure rate of 1% in the morbid obesity
subsample. However, morbidly obese patients
were never seen for neuropsychological evaluation,
and therefore this diagnostic category is not repre-
sented in the current study.
Performance validity test (PVT): Amsterdam
Short-Term Memory Test (ASTM)
The ASTM is a measure of cognitive underperfor-
mance and involves a forced-choice word recogni-
tion procedure (Schmand & Lindeboom, 2005).
The number of correct recognitions are summed
(range 0–90), with lower scores reflecting poorer
performance. We used a cutoff score of 82. In the
original validation studies that compared 84
experimental malingerers and 206 patients suffer-
ing from neurological conditions such as cerebral
contusion, advanced Parkinson disease, stroke,
multiple sclerosis, and severe epilepsy, this cut
score was associated with a specificity of 98% and
a sensitivity of 77% (Schmand & Lindeboom,
2005). In the initial sample, 29.9% of the patients
failed on the ASTM (i.e., <82). The four main
diagnostic subgroups did not differ with regard to
failure rates on the ASTM (range = 25–37%).
Clinician checklist
Clinicians completed a checklist3 after their inter-
view with the patient and after they had seen the
patient files, but before the test session took place.
Probing symptom distortion was not part of the
interview, and patient files rarely contained infor-
mation directly addressing diagnostic options such
as feigning or malingering. Files could contain
information about previous neuropsychological
assessments including SVT/PVT results. However,
for the vast majority of the neuropsychological
assessments, such prior information was not
available.
The checklist addressed the following patient
variables: age, gender, education, referring doctor,
diagnosis upon referral, medication, social situa-
tion, employment status, type of income, and cur-
rent involvement in legal proceedings. The final
item asked clinicians to predict on a 3-point
Likert scale (i.e., unproblematic–somewhat proble-
matic–problematic) the outcome of subsequent
response validity testing. Experts endorsed the pro-
blematic option only four times, and therefore we
combined the problematic and somewhat proble-
matic categories.
Exit questionnaire for clinicians
The exit questionnaire focused on the following
items: name, age, function, years of work experi-
ence, estimated number of diagnostic assessments
in the past year, type of diagnostic assessment
(neuropsychological, psychological or both), and
experience with forensic evaluations and, if so,
the number of forensic evaluations in the past
year. Clinicians were queried about how often
they included response validity tests in their test
batteries (i.e., always, in certain situations, never).
When they said they incorporated SVTs/PVTs
only under certain conditions, they were asked to
tick one or more options that listed potential con-
ditions (e.g., when the patient is involved in litiga-
tion). Furthermore, clinicians indicated on a 10-
point Likert scale (0 = not at all; 10 = very
strongly) whether participating in this study had
sensitized them to distorted symptom presentation
during their interview with the patient.
Procedure
Prior to testing, patients received an information
letter about the current study, and they gave
informed consent to use their anonymized test
data for this study. The information letter con-
tained a brief description of what a psychological
assessment entails. The letter explained that in
order to obtain valid diagnostic data, it is impor-
tant that patients exert optimal effort at the cogni-
tive tests and fill out the psychological
questionnaires as accurately as possible. Next, the
letter explained that sometimes patients do not
3The checklist may be obtained from the first author upon request.
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succeed in this, and that the study addressed the
question of how this can be measured. When the
hospital’s standard test battery did not include the
SIMS and/or ASTM, these tests were added to the
protocol. Tests were administered either by a cer-
tified psychological technician or by trained clin-
ical psychology doctoral students working under
the supervision of a certified psychologist. All of
them were familiar with the SIMS and the ASTM
and had experience with administering these tests.
Results
Clinicians’ prediction of response validity
For 152 cases (74.9%), clinicians predicted that the
response validity would be unproblematic, while
for 51 cases (25.1%), they predicted it to be (some-
what) problematic. Table 3 shows how clinicians’
predictions relate to passing or failing both SIMS
and ASTM. Of the 152 patients who were expected
to produce unproblematic response validity test
scores, 14 patients (9.2%) failed both tests. Of the
51 patients who were anticipated to produce at
least somewhat problematic SVT/PVT test results,
35 patients (68.6%) passed both tests. For 16 out
the 30 patients (53.3%) who failed both tests, clin-
icians predicted correctly that distorted symptom
presentation might be an issue. Overall, clinical
prediction and test outcome agreed in 76% of the
cases. The corresponding Cohen’s kappa was .26
(p < .001, 95% CI [.08, .44]), which according to
widely used standards would be qualified as fair
(Landis & Koch, 1977). However, given the severe
consequences of misclassifications in this type of
clinical decision making, and considering the fact
that clinicians were only right about half of time in
their prediction of the 30 cases of distorted symp-
tom presentation, we would evaluate this level of
agreement as poor.
Clinicians’ use of response validity tests in
clinical assessments
The majority of the clinicians (i.e., 72.4%) stated
that only in certain situations would they add
SVTs/PVTs to their test battery (see Table 1).
The most frequently reported situations were:
how symptoms are presented by patients (100%),
certain types of symptoms reported during the
interview (95.5%), and the presence of incentives
(90.9%). Taking part in this study led to an
increased alertness to the issue of distorted symp-
tom presentation (mean score of 5.9; range = 1–9).
Discussion
We had anticipated that neuropsychologists would
not be particularly accurate in their prediction of
distorted symptom presentation. Agreement
between neuropsychologists’ predictions and
actual test outcome was, indeed, far from perfect,
as indicated by a relatively low Cohen’s kappa. For
patients who failed both SIMS and ASTM, clini-
cians’ predictions were at chance level (i.e., hit rate
of 53.3%). Furthermore, we expected that neurop-
sychologists would underestimate the occurrence
of poor response validity. Contrary to this, how-
ever, neuropsychologists overestimated the fre-
quency of distorted symptom reports. That is,
14.7% of the patients failed both SIMS and
ASTM, whereas a (somewhat) problematic out-
come was predicted for 25.1% of the assessments.
This pattern deviates from those of Faust and
colleagues (Faust, Hart, & Guilmette, 1988; Faust,
Hart, Guilmette, & Arkes, 1988), who found that
clinicians underestimated the occurrence of dis-
torted symptom reports. It may well be that our
study sensitized clinicians to the topic and that this
was conducive to overprediction of symptom dis-
tortion. Indeed, on the exit questionnaire, neurop-
sychologists often indicated that participation in
the study had made them more aware of the diag-
nostic option of distorted symptom presentation.
When clinicians are alerted to the possibility of
poor response validity, this may lead them to ques-
tion genuine symptoms (e.g., Rosenhan, 1973). For
example, compared with earlier studies (Faust,
Hart, & Guilmette, 1988; Faust, Hart, Guilmette,
& Arkes, 1988), Trueblood and Binder (1997)
found relatively low levels of false negatives (i.e.,
missing cases of distorted symptom presentation).
However, three out of 26 clinicians (11.5%) in that
Table 3. Neuropsychologists’ prediction versus test perfor-
mance.
SIMS and ASTM
Neuropsychologists’ prediction Pass both Fail both n
Unproblematic 138 14 152
(Somewhat) problematic 35 16 51
n 173 30 203
Note. N = 203. SVT = Symptom Validity Test; SIMS = Structured
Inventory of Malingered Symptomatology; ASTM = Amsterdam
Short-Term Memory Test.
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study generated false positives (i.e., misclassifying
genuine cognitive impairments as a form of dis-
torted symptom presentation). Thus, clinicians’
sensitivity to distorted symptom presentation may
come with the price of misclassifying genuine
symptom reports as not valid.
In our study, 9.2% of the patients failed on both
the SIMS and the ASTM, when neuropsychologists
had expected in their cases a nondistorted symptom
presentation. This percentage illustrates the risk of
relying too much on clinical judgment: Clinicians
may decide not to include SVTs and/or PVTs in
their test batteries, which means that they miss an
opportunity to provide themselves with critical
feedback on their incorrect initial impression.
In line with previous survey findings
(Dandachi-FitzGerald et al., 2013), the majority
of neuropsychologists reported that prior to parti-
cipation in this study, they did not administer
SVTs and/or PVTs routinely in clinical assess-
ments. Rather, they added response validity tests
to their test battery when certain features were
present. These features were related to clinicians’
perception of how patients present their problems,
and so they were intrinsically subjective. The pre-
sent results show that clinicians are well advised
not to lean too much on such impressions.
Relatedly, clinicians said that the presence of
incentives served as an important cue for the deci-
sion to include SVTs and/or PVTs. However,
patients might not wish to inform their clinicians
about their anticipation of financial or legal advan-
tages (Van Egmond, Kummeling, & Balkom,
2005). Thus, making the decision to include
response validity tests contingent on information
about such incentives is an imperfect rule of
thumb. More generally, it is illogical to use a less
accurate method (i.e., subjective judgment) to
decide whether or not to employ a more accurate
method.
Older studies on clinical prediction of distorted
symptom presentation (Faust, Hart, & Guilmette,
1988; Faust, Hart, Guilmette, & Arkes, 1988;
Heaton et al., 1978) were criticized for being too
artificial (Bigler, 1990; Garb & Schramke, 1996;
Schmidt, 1989). Critics pointed out that clinicians
do not solely rely on test data to determine the
presence of cognitive impairment or psychopathol-
ogy. Rather, they would consider psychometric
data along with information from the medical his-
tory, the clinical interview, and the observations.
However appealing and intuitively plausible this
point might seem, there is little evidence that judg-
ment accuracy increases as clinicians consider
more sources of clinical data (e.g., Garb, 2005;
Wedding & Faust, 1989). In fact, several studies
have found the opposite: The more information
that clinicians try to take into account, the less
accurate their judgment becomes (e.g., Ægisdóttir
et al., 2006; Sawyer, 1966; Wedding, 1983). In the
current study, we tried to stay close to the daily
practice of diagnostic assessment in a hospital set-
ting. Thus, neuropsychologists did have all the
clinical data at their disposal to inform their opi-
nion (i.e., the medical file, their interview, observa-
tional data). Nonetheless, their predictions about
distorted symptom presentation were wrong in
24% of the cases.
Several limitations of the current study deserve
comment. Firstly, although they came from five
different hospitals, our group of neuropsycholo-
gists was relatively small. This limits the general-
izability of our findings. Also, neuropsychologists
participated on a voluntary basis, and the proce-
dure sensitized them to the issue of distorted
symptom presentation. Thus, our findings may
underestimate how poor clinical prediction of dis-
torted symptom prediction really is.
Secondly, although we did include outcomes
from two different response validity tests—one
SVT and one PVT—our study relied on only two
response validity tests. Results might have been
different, had we used a whole battery of such
tests. Clearly, this issue warrants further study.
Thirdly, we used a 3-point Likert scale (i.e., unpro-
blematic–somewhat problematic–problematic) to
index clinicians’ predictions of response validity
test outcome. The problematic option, however,
was only endorsed four times. Considering that
clinicians were asked to make a prediction without
having neuropsychological test results at their dis-
posal, it is conceivable that they felt more comfor-
table to predict a “somewhat problematic” than a
“problematic” outcome of response validity testing.
Thus, the distinction between these two categories
may reflect more the degree of confidence that
clinicians placed in their suspicion of distorted
symptom presentation than the number of indica-
tions that pointed in the direction of symptom
distortion. In retrospect, it would have been better
if we had used a dichotomous index of poor
response validity (yes /no) and additionally had
asked clinicians to rate the confidence they placed
in their judgments.
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We focused on clinicians’ predictions of dis-
torted symptom presentation in a hospital setting,
a setting where the base rate of distorted symptom
presentation will be lower than in the forensic
context (Dandachi-FitzGerald et al., 2013;
Mittenberg et al., 2002). Given the relatively low
base rate of distorted symptom presentation, a
good decisional strategy in a hospital setting
would be to anticipate nondistorted symptom pre-
sentation, and to include response validity tests as
a check on this assumption. Of course, this is only
true to the extent that clinicians are sensitive to the
psychometric information provided by response
validity tests, notably their positive and negative
predictive power. The issue of clinicians’ predic-
tion of response validity test outcomes warrants
further research, in particular research in which
purely clinical cases are compared with cases that
have a forensic dimension.
Taken together, our results support the notion
that it is important to routinely test for distorted
symptom presentation (Bush et al., 2005;
Heilbronner et al., 2009). Yet, our findings are
silent about how clinicians will integrate response
validity test scores in their diagnostic conclusions.
What happens when their a priori predictions do
not match test results? Does this, indeed, lead to a
correction of their prediction or do clinicians cling
to their first impressions? Clearly, this too is an
important topic for future research.
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